WO1997033579A1 - Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption - Google Patents

Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption Download PDF

Info

Publication number
WO1997033579A1
WO1997033579A1 PCT/GB1997/000663 GB9700663W WO9733579A1 WO 1997033579 A1 WO1997033579 A1 WO 1997033579A1 GB 9700663 W GB9700663 W GB 9700663W WO 9733579 A1 WO9733579 A1 WO 9733579A1
Authority
WO
WIPO (PCT)
Prior art keywords
paracellular
receptor agonist
absoφtion
naratriptan
δht
Prior art date
Application number
PCT/GB1997/000663
Other languages
English (en)
Inventor
Jeremy Bharat Desai
Laurence Francis Lacey
Sheila Irene Schwartz
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605328.5A external-priority patent/GB9605328D0/en
Priority claimed from GBGB9605329.3A external-priority patent/GB9605329D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to AU21040/97A priority Critical patent/AU2104097A/en
Publication of WO1997033579A1 publication Critical patent/WO1997033579A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Abstract

L'invention se rapporte à un procédé destiné à améliorer l'absorption de composés qui agissent comme agonistes du récepteur de type 5HT1 après administration par voie orale ou intranasale. L'invention se rapporte également à des compositions pharmaceutiques destinées à une administration par voie orale ou intranasale des agonistes du récepteur de type 5HT1 et d'activateurs paracellulaires d'absorption. Ces activateurs paracellulaires d'absorption augmentent la vitesse d'absorption de l'agoniste du récepteur de type 5HT1. Le récepteur de type 5HT1 approprié destiné à être utilisé dans l'invention comprend sumatriptan, naratriptan et 4-[3-(trans-3-diméthylaminocyclobutyl)1-H-indol-5-ylméthyl]-(4S)oxazolidin-2-one.
PCT/GB1997/000663 1996-03-13 1997-03-11 Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption WO1997033579A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21040/97A AU2104097A (en) 1996-03-13 1997-03-11 Medicaments comprising 5ht1-like receptor agonists with an increased absorption

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9605328.5 1996-03-13
GBGB9605328.5A GB9605328D0 (en) 1996-03-13 1996-03-13 Medicaments
GBGB9605329.3A GB9605329D0 (en) 1996-03-13 1996-03-13 Medicaments
GB9605329.3 1996-03-13

Publications (1)

Publication Number Publication Date
WO1997033579A1 true WO1997033579A1 (fr) 1997-09-18

Family

ID=26308928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/000663 WO1997033579A1 (fr) 1996-03-13 1997-03-11 Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption

Country Status (2)

Country Link
AU (1) AU2104097A (fr)
WO (1) WO1997033579A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016761A2 (fr) * 1998-09-18 2000-03-30 Alcon Laboratories, Inc. Agonistes de 5ht2 serotoninergiques utiles pour traiter le glaucome
WO2004093917A2 (fr) * 2003-04-22 2004-11-04 Nastech Pharmaceutical Company Inc. Administration de triptans par voie intranasale
US6881749B2 (en) 2001-06-01 2005-04-19 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US6960608B2 (en) 2001-06-01 2005-11-01 Alcon, Inc. Fused indazoles and indoles and their use for the treatment of glaucoma
US7071225B2 (en) 2001-06-01 2006-07-04 Alcon, Inc. Arylaminopropane analogues and their use for the treatment of glaucoma
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522A (en) * 1984-08-01 1986-02-05 Glaxo Group Ltd An indole derivative
EP0308181A1 (fr) * 1987-09-14 1989-03-22 Novo Nordisk A/S Formulations à délivrance transmucosale et méthode de préparation
GB2208646A (en) * 1987-08-13 1989-04-12 Glaxo Group Ltd Indole derivatives
WO1995020588A1 (fr) * 1994-01-26 1995-08-03 The Wellcome Foundation Limited Derives d'indole formant des agonistes de la 5-ht¿1?

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522A (en) * 1984-08-01 1986-02-05 Glaxo Group Ltd An indole derivative
GB2208646A (en) * 1987-08-13 1989-04-12 Glaxo Group Ltd Indole derivatives
EP0308181A1 (fr) * 1987-09-14 1989-03-22 Novo Nordisk A/S Formulations à délivrance transmucosale et méthode de préparation
WO1995020588A1 (fr) * 1994-01-26 1995-08-03 The Wellcome Foundation Limited Derives d'indole formant des agonistes de la 5-ht¿1?

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOUNIR MESIHA ET AL.: "increased oral absorption of insulin by medium viscosity hydroxypropyl cellulose", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 114, no. 2, 1995, pages 137 - 149, XP000673693 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016761A2 (fr) * 1998-09-18 2000-03-30 Alcon Laboratories, Inc. Agonistes de 5ht2 serotoninergiques utiles pour traiter le glaucome
WO2000016761A3 (fr) * 1998-09-18 2000-05-25 Alcon Lab Inc Agonistes de 5ht2 serotoninergiques utiles pour traiter le glaucome
US6664286B1 (en) 1998-09-18 2003-12-16 Alcon Manufacturing, Ltd. Serotonergic 5ht2 agonists for treating glaucoma
US6881749B2 (en) 2001-06-01 2005-04-19 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
US6960608B2 (en) 2001-06-01 2005-11-01 Alcon, Inc. Fused indazoles and indoles and their use for the treatment of glaucoma
US7071225B2 (en) 2001-06-01 2006-07-04 Alcon, Inc. Arylaminopropane analogues and their use for the treatment of glaucoma
WO2004093917A2 (fr) * 2003-04-22 2004-11-04 Nastech Pharmaceutical Company Inc. Administration de triptans par voie intranasale
WO2004093917A3 (fr) * 2003-04-22 2005-04-14 Nastech Pharm Co Administration de triptans par voie intranasale
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration

Also Published As

Publication number Publication date
AU2104097A (en) 1997-10-01

Similar Documents

Publication Publication Date Title
US5597844A (en) Cimetidine granules coated with a partially hydrogenated vegetable oil
US5456918A (en) Ranitidine pharmaceutical compositions
US5624677A (en) Controlled release of drugs delivered by sublingual or buccal administration
AU650706B2 (en) Medicaments
US5888534A (en) Controlled release of drugs delivered by sublingual or buccal administration
JP2965704B2 (ja) オンダンセトロンを含有する経口組成物
CA2074215C (fr) Formulations orales ameliorees de nucleosides a base de dideoxypurine
US5468504A (en) Effervescent pharmaceutical compositions
FR2727016A1 (fr) Compositions pharmaceutiques a base d'ondansetron
NO175131B (no) Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin
US5578632A (en) Medicaments for the treatment of gastrointestinal dysfunction
KR20010041110A (ko) 트라마돌을 함유하는 약제학적 배합물
WO1997033579A1 (fr) Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption
CA2081344C (fr) Utilisation des antagonistes des recepteurs 5-ht4 pour le traitement des arythmies et des accidents vasculaires cerebraux
SK279211B6 (sk) Sulfátová soľ substituovaného triazolu, spôsob jej
EP1171134A1 (fr) Liberation controlee de sildenafil administre par voie sublinguale ou orale
US20020099059A1 (en) Combination therapy for the treatment of migraine
JP7270901B2 (ja) 男性の避妊のための非ホルモン性組成物および方法
EP0777470A1 (fr) Utilisation d'agent augmentant l'absorption paracellulaire tel que la glucose pour ameliorer l'absorption d'antagonistes histaminiques-h2
AU654313B2 (en) Pharmaceutical compositions
EP0574624B1 (fr) Compositions pharmaceutiques
NO179996B (no) Brusede preparater inneholdende 5HT1-lignende reseptorantagonister

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97532363

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase